Antiviral evaluation of peptides conjugated with gallic acid against the virus SARS-CoV-2 using subgenomic replicon

• Grant number: 22/11644-5
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: December 01, 2022
• End date: November 30, 2024
• Field of knowledge: Biological Sciences - Microbiology
• Principal Investigator: Paulo Ricardo da Silva Sanches
• Grantee: João Caldana Elias de Campos Faria
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

Pandemics caused by viruses such as SARS-CoV-2, which present high and quick spreading, highlight the emergency for the development of efficient treatments against this and other diseases. Peptides and bioconjugates have been showing promissory results as antivirals, inhibiting different steps of the virus life cycle. Peptides are advantageous compared to small molecules due to their high selectivity, fast action, and biodegradability and can be modified by synthetic methods in the laboratory. The objective of this project is to evaluate the antiviral potential of bioconjugates against SARS-CoV-2 using a subgenomic replicon and evaluate the cytotoxicity of these compounds in human cell strains such as lung, kidney, liver, and human erythrocytes.

Scientific publications

(The scientific publications listed on this page originate from the Web of Science or SciELO databases. Their authors have cited FAPESP grant or fellowship project numbers awarded to Principal Investigators or Fellowship Recipients, whether or not they are among the authors. This information is collected automatically and retrieved directly from those bibliometric databases.)

SANCHES, PAULO RICARDO DA S.; FARIA, JOAO CALDANA ELIAS DE CAMPOS; BITTAR, CINTIA; OLIVIERI, HUGO ALEXANDRE SIQUEIRA GUBEROVICH; MESQUITA, NATHALYA CRISTINA DE MORAES ROSO; NOSKE, GABRIELA DIAS; DE GODOY, ANDRE SCHUTZER; OLIVA, GLAUCIUS; RAHAL, PAULA; CILLI, EDUARDO MAFFUD. The GA-Hecate Peptide inhibits the ZIKV Replicative Cycle in Different Steps and can Inhibit the Flavivirus NS2B-NS3 Protease after Cell Infection. PROTEIN AND PEPTIDE LETTERS, v. 31, n. 7, p. 12-pg., 2024-07-19. (22/11644-5, 20/05761-3, 22/05411-8, 19/08342-4, 13/07600-3, 20/12519-4, 15/23244-8)